[Efficacy and safety of Camrelizumab and AVD in the first-line treatment of classic Hodgkin's lymphoma].
作者信息
Zhao K, Wang H Q, Li L, Song T, Li S P, Qiu M H
机构信息
Department of Oncology, Tianjin Union Medical Center, Tianjin Cancer Institute of Integrated Traditional Chinese and Western Medicine, the Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin 300121, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 May 14;43(5):431-434. doi: 10.3760/cma.j.issn.0253-2727.2022.05.015.
Abstract
摘要
相似文献
1
[Efficacy and safety of Camrelizumab and AVD in the first-line treatment of classic Hodgkin's lymphoma].卡瑞利珠单抗联合AVD一线治疗经典型霍奇金淋巴瘤的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2022 May 14;43(5):431-434. doi: 10.3760/cma.j.issn.0253-2727.2022.05.015.
2
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.本妥昔单抗维迪昔联合 ABVD 或 AVD 方案用于治疗初诊霍奇金淋巴瘤患者的 1 期、开放标签、剂量递增研究。
Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.
3
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.ABVD 方案中省略达卡巴嗪或博来霉素或两者在治疗早期有利霍奇金淋巴瘤（GHSG HD13）中的应用：一项开放标签、随机、非劣效性试验。
Lancet. 2015 Apr 11;385(9976):1418-27. doi: 10.1016/S0140-6736(14)61469-0. Epub 2014 Dec 22.
4
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.苯达莫司汀联合维布妥昔单抗治疗 III 或 IV 期霍奇金淋巴瘤的总生存。
N Engl J Med. 2022 Jul 28;387(4):310-320. doi: 10.1056/NEJMoa2206125. Epub 2022 Jul 13.
5
Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.卡瑞利珠单抗，一种针对程序性死亡受体 1 的人源化单克隆抗体的现状与展望。
Recent Pat Anticancer Drug Discov. 2021;16(3):312-332. doi: 10.2174/1574892816666210208231744.
6
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.本妥昔单抗联合化疗治疗Ⅲ期或Ⅳ期经典型霍奇金淋巴瘤（ECHELON-1）：一项国际、开放标签、随机、3期试验的5年随访结果
Lancet Haematol. 2021 Jun;8(6):e410-e421. doi: 10.1016/S2352-3026(21)00102-2.
7
Pembrolizumab for classical Hodgkin's lymphoma.帕博利珠单抗用于经典型霍奇金淋巴瘤。
Lancet Oncol. 2016 Aug;17(8):e324. doi: 10.1016/S1470-2045(16)30301-1. Epub 2016 Jul 7.
8
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.纳武利尤单抗联合 AVd 方案治疗早期不良预后经典型霍奇金淋巴瘤的疗效：德国霍奇金研究组 NIVAHL 随机 2 期试验。
JAMA Oncol. 2020 Jun 1;6(6):872-880. doi: 10.1001/jamaoncol.2020.0750.
9
Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.低剂量地西他滨联合抗 PD-1 抗体卡瑞利珠单抗治疗复发/难治性经典型霍奇金淋巴瘤。
J Clin Oncol. 2019 Jun 10;37(17):1479-1489. doi: 10.1200/JCO.18.02151. Epub 2019 Apr 30.
10
Penpulimab: First Approval.派姆单抗：首次批准。
Drugs. 2021 Dec;81(18):2159-2166. doi: 10.1007/s40265-021-01640-9.
本文引用的文献
1
Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.用于预测霍奇金淋巴瘤和弥漫性大B细胞淋巴瘤治疗结果的基线PET/CT成像参数：一项系统评价
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3198-3220. doi: 10.1007/s00259-021-05233-2. Epub 2021 Feb 18.
2
Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study.《儿童、青少年和青年霍奇金淋巴瘤患者的临床特征和治疗结局：KPHOG 淋巴瘤工作组的一项多中心回顾性研究》。
J Korean Med Sci. 2020 Nov 30;35(46):e393. doi: 10.3346/jkms.2020.35.e393.
3
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.帕博利珠单抗联合 AVd 方案治疗未经治疗的早期不利和晚期经典型霍奇金淋巴瘤。
Blood. 2021 Mar 11;137(10):1318-1326. doi: 10.1182/blood.2020007400.
4
The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas.淋巴瘤成人患者治疗前后 FDG PET/CT 代谢参数的贡献。
Ann Nucl Med. 2020 Oct;34(10):707-717. doi: 10.1007/s12149-020-01521-3. Epub 2020 Sep 13.
5
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.霍奇金淋巴瘤，2.2020 年版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2020 Jun;18(6):755-781. doi: 10.6004/jnccn.2020.0026.
6
Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.原发性治疗与经典型霍奇金淋巴瘤的相对生存率：荷兰 1989-2017 年全国性基于人群的研究。
Leukemia. 2021 Feb;35(2):494-505. doi: 10.1038/s41375-020-0875-0. Epub 2020 May 28.
7
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.纳武利尤单抗联合 AVd 方案治疗早期不良预后经典型霍奇金淋巴瘤的疗效：德国霍奇金研究组 NIVAHL 随机 2 期试验。
JAMA Oncol. 2020 Jun 1;6(6):872-880. doi: 10.1001/jamaoncol.2020.0750.
8
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients.基线 18F-FDG PET/CT 代谢参数在老年 HL 中的预后作用：123 例患者的双中心经验。
Ann Hematol. 2020 Jun;99(6):1321-1330. doi: 10.1007/s00277-020-04039-w. Epub 2020 Apr 24.
9
A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma.卡瑞利珠单抗治疗复发或难治性经典型霍奇金淋巴瘤的单臂、多中心、Ⅱ期研究。
Clin Cancer Res. 2019 Dec 15;25(24):7363-7369. doi: 10.1158/1078-0432.CCR-19-1680. Epub 2019 Aug 16.
10
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.纳武利尤单抗治疗新诊断的晚期经典型霍奇金淋巴瘤：CheckMate 205 研究的 II 期安全性和疗效。
J Clin Oncol. 2019 Aug 10;37(23):1997-2007. doi: 10.1200/JCO.19.00315. Epub 2019 May 21.
Zotero 插件